Prism Medico & Pharmacy Limited has submitted another regulatory compliance intimation with stock exchanges regarding its non-convertible securities position. The company has confirmed that no non-convertible securities were issued during the latest reporting period.

Latest Regulatory Filing

The company filed its most recent intimation on April 6, 2026, addressing both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI). This filing was made pursuant to Regulation 57(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Non-Convertible Securities Confirmation

Prism Medico and Pharmacy Limited has declared that it has not issued any non-convertible securities during the quarter beginning January 1, 2026 and ending March 31, 2026. Consequently, there were no interest, dividend, or principal obligations due for payment during this period. This represents a continuation of the company's position on non-convertible securities.

Previous Compliance Record

The company had previously filed a similar intimation on March 30, 2026, under Regulation 57(4) for the quarter period April 1, 2026 to June 30, 2026, also confirming no non-convertible securities with payable obligations.

Company Information

The latest filing was signed by Davender Singh, Director of the company, bearing DIN: 09447213. The company operates under CIN: L24100HP2002PLC009299 with its registered office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Prism medico & pharmacy Limited has issued a regulatory clarification to stock exchanges regarding significant movement in its security price, attributing the fluctuations to market-driven speculation rather than any undisclosed material information.

Regulatory Disclosure Details

The company submitted its clarification on February 27, 2026, to both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in response to exchange queries about recent price movements in the company's securities.

Management's Position on Price Movement

The company management emphasized that all material information bearing on operations and performance has been regularly disclosed to stock exchanges in a timely and accurate manner. The disclosure confirms compliance with corporate governance principles outlined in Regulation 4 of SEBI regulations and related circulars.

According to the company's statement, the price movement is purely attributed to:

• Market conditions and market-driven factors
• Speculative trading activities
• Factors beyond management control

Key Compliance Confirmations

The company provided several important confirmations in its regulatory filing:

Ongoing Regulatory Commitment

Prism Medico and Pharmacy Limited reiterated its commitment to maintaining transparency with stock exchanges and investors. The company confirmed it will continue to inform exchanges about any price-sensitive information as mandated under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The clarification was signed by Davender Singh, Director of the company (DIN: 09447213), emphasizing the management's direct involvement in ensuring regulatory compliance and transparent communication with stakeholders.